Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.62 |
| ▸ | HTR1A | P08908 | 7/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240518 | 0.89 | HTR2C (0.62) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL377800 | 0.87 | HTR2C (0.63) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL949252 | 0.84 | SLC18A3 (0.68) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL8484170 | 0.83 | HTR1A (0.54) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL26154104 | 0.83 | PARP10 (0.50) | SLC6A2SLC6A4SLC6A3HTR1APARP10 | |
| Hydrochloric Acid SCHEMBL31615878 | 0.82 | SLC18A3 (0.66) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL25255641 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL1237703 | 0.81 | HTR2C (0.55) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL8285669 | 0.81 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| Hydrochloric Acid SCHEMBL31615877 | 0.80 | HTR2C (0.81) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028403-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-11814375-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4028403-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-114269755-A | 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210094943-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2021048242-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0958280-B1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6838470-B2 | Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814375-B2 | Heterocyclic compounds | CYP1B1, CYP1A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A2 4473/4885SLC6A4 4414/4885SLC6A3 4560/4885 |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | SLC6A2 1753/4885SLC6A4 1640/4885SLC6A3 1588/4885 |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, NR3C2 | SLC6A2 1360/4885SLC6A4 1538/4885SLC6A3 1160/4885 |
| US-20210094943-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | SLC6A2 4533/4885SLC6A4 4487/4885SLC6A3 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.